Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know

Corcept Therapeutics Incorporated (NASDAQ: CORT ) shares soared 21.95% to $113.35 after the bell on Wednesday following the announcement of second-quarter results, where both revenue and earnings per share topped analyst estimates. Revenue and EPS Sail Past Analyst Targets The California-based biopharmaceutical company reported second-quarter revenue of $256.1 million for the period ended June 30, up from $194.4 million a year earlier. This revenue beat analyst estimates of $219.32 million by 16.8%. EPS probably draws the most attention for investor optimism. It came in at $0.36, compared with the expected $0.02, representing a 1,700% beat. Lifyorli Launch, Raised Guidance Add Fuel According to the company announcement, Lifyorli, Corcept’s oncology drug used with nab-paclitaxel chemotherapy, generated $47.6 million in its first full quarter since Food and Drug Administration app...